Answers are grounded in this paper and cite their sources.
To the Editor: Tumor necrosis factor (TNF) is recognized as an important cytokine in the pathogenesis of Crohn's disease (CD), and TNF blockade has been effective in the treatment of patients with CD. The first biologic agent shown to induce and maintain remission in patients with CD is infliximab, a chimeric antibody to TNF-α.1 Infliximab is classified as a category B drug for pregnant women. Adalimumab (Humira) is a recombinant human immunoglobin G1 monoclonal antibody targeting TNF that is approved for the treatment of moderate to severe rheumatoid arthritis as well as psoriatic arthritis. It has demonstrated efficacy for induction of remission in CD.2,–4 There are few data about its use during pregnancy. We report a successful pregnancy in a woman with infliximab-resistant CD treated with adalimumab. A 35-year-old woman with longstanding ileocolonic CD, diagnosed in 1995, had been treated with multiple medications and was either unresponsive to or intolerant of 5-aminosalicylic acid, antibiotics, and purine analogues. She underwent subtotal colectomy and ileorectal anastomosis in 1999. The patient developed recurrent small bowel disease in 2002, and infliximab was started, initially with a good clinical response. However, over time, she required an increase in her dosage and a shortened infusion interval to every 4 to 6 weeks. While on therapy, colonoscopy demonstrated active CD in the distal 45 cm of the neoterminal ileum. Corticosteroids were started. The patient declined treatment with methotrexate and consequently was started on adalimumab 80 mg followed by 40 mg subcutaneously every other week. Her condition improved, and she was able to be tapered off her steroids during the next several weeks. Seven months after starting adalimumab, she became pregnant. After discussions with the patient, a decision was made to continue the adalimumab throughout her pregnancy. She had a brief admission at 20 weeks' gestation for an unexplained fever and abdominal pain treated with a 2-week course of steroids for a presumed flare of her CD, without any endoscopic studies or imaging performed. She delivered a normal, full-term male infant vaginally. The patient remains on adalimumab and is breastfeeding her newborn. The baby is now 6 months old with normal growth and development. The treatment of inflammatory bowel disease in pregnancy is a concern for both patients and their physicians. It is accepted that maintenance of remission of inflammatory bowel disease is associated with a successful pregnancy and that active inflammatory bowel disease has been shown to be a factor associated with poor pregnancy outcomes.5 Accumulating data support the safety of intentional or inadvertent use of infliximab in pregnancy.6,7 These data suggest that the benefits of infliximab in achieving response and maintaining remission in mothers with CD may outweigh the potential risk to the fetus from exposure to the drug. Adalimumab is a category B drug in pregnancy. Small animal studies in pregnant monkeys have not demonstrated adverse effects of adalimumab. There is 1 English language case report describing the successful use of adalimumab started before conception and continued throughout the pregnancy.8 In this report, the patient also suffered from infliximab-resistant CD, and despite severely active disease at conception and moderate activity in the third trimester, the pregnancy was uncomplicated. When evaluating medications in women who are pregnant or contemplating pregnancy, it is important to address the safety regarding the ability to conceive, teratogenicity, risk of miscarriage, and complications for the child. This decision should be made on an individual basis. In this case, adalimumab induced and maintained remission of infliximab-refractory CD without any apparent side effects to the mother or child. A registry of women who received adalimumab during pregnancy has been initiated, and physicians are encouraged to report such patients (toll-free 877–311–8972).
No takes yet. Share an insight, caveat, or question.
Mishkin et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: